Evotec’s (EVO) “Buy” Rating Reiterated at HC Wainwright

Evotec (NASDAQ:EVO)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $4.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 177.01% from the company’s current price.

Several other analysts also recently commented on the stock. TD Cowen downgraded shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a research report on Wednesday, July 15th. Weiss Ratings lowered shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 25th. Finally, Berenberg Bank downgraded Evotec from a “buy” rating to a “hold” rating in a research note on Thursday, July 16th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $3.00.

Evotec Stock Up 7.4%

Shares of Evotec stock traded up $0.10 during midday trading on Wednesday, hitting $1.44. The company had a trading volume of 62,205 shares, compared to its average volume of 102,523. The company has a 50 day moving average of $1.78 and a 200 day moving average of $2.37. Evotec has a 52-week low of $1.33 and a 52-week high of $4.27. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.21 and a current ratio of 2.33.

Institutional Trading of Evotec

A number of large investors have recently made changes to their positions in the stock. Apollon Wealth Management LLC bought a new position in Evotec during the first quarter valued at approximately $28,000. SmartHarvest Portfolios LLC purchased a new stake in Evotec in the first quarter worth approximately $44,000. Optiver Holding B.V. grew its position in Evotec by 598.4% in the 1st quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock worth $709,000 after purchasing an additional 242,973 shares during the period. Finally, WCM Investment Management LLC grew its position in Evotec by 12.1% in the 1st quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock worth $1,480,000 after purchasing an additional 67,917 shares during the period. 5.81% of the stock is currently owned by institutional investors.

Evotec Company Profile

Evotec SE is a life sciences company headquartered in Hamburg, Germany, that provides drug discovery and development services to pharmaceutical, biotechnology and academic partners. Founded in 1993, the company supports programs from early-stage research through preclinical and clinical development, with expertise in small-molecule and biologic therapies.

Its activities include target identification and validation, screening, medicinal chemistry, pharmacology, drug manufacturing support and development services.